MedPath

Fuchs' Torsional Phaco Study

Phase 4
Completed
Conditions
Fuchs' Endothelial Dystrophy
Phacoemulsification
Interventions
Procedure: Phacoemulsification
Registration Number
NCT00781027
Lead Sponsor
Maastricht University Medical Center
Brief Summary

The primary objective is to compare the effect of torsional phacoemulsification and longitudinal phacoemulsification on central and peripheral corneal thickness/volume after cataract surgery in patients with Fuchs' endothelial dystrophy.

Detailed Description

Fuchs' endothelial dystrophy is a progressive, bilateral disease of the corneal endothelium, which eventually leads to corneal decompensation. In the early stage, some patients develop visually significant cataract. During cataract surgery ultrasound (US) power is used to emulsify the lens, which leads to endothelial cell loss and tissue damage. The reduction of US power has become the primary surgical goal in cataract surgery, which is especially important in patients with Fuchs' endothelial dystrophy to limit endothelial cell loss.

In 2006, Alcon Surgical introduced a torsional mode in its phacoemulsification system (Infiniti Vision System). It includes a handpiece that produces rotary oscillations of the phacoemulsification tip and is suggested to reduce the amount of US power required to remove the cataractous nucleus, because it does not produce repulsion and breaks up the cataract by shearing and not by the conventional jackhammer effect. This reduction in US power, could lead to less endothelial cell damage than the conventional (longitudinal) mode, which is reported recently for patients with hard cataract. It is important to investigate patients with Fuchs' endothelial dystrophy, because patients with a compromised endothelial cell layer will benefit the most from less endothelial cell damage. Consequently, this lower level of endothelial damage may postpone the date of keratoplasty.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
50
Inclusion Criteria
  • Patients diagnosed with Fuchs' endothelial dystrophy (all stages) and planning to undergo cataract surgery due to visually significant cataract
  • Patients should be 40 years of age or older
Exclusion Criteria
  • Patients with Fuchs' dystrophy with a history of previous corneal or intraocular surgery
  • Patients with a planned combined surgical procedure
  • Patients who have other vision-affecting disorders than Fuchs' endothelial dystrophy

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
1PhacoemulsificationTorsional phacoemulsification
2PhacoemulsificationLongitudinal phacoemulsification
Primary Outcome Measures
NameTimeMethod
Change in central corneal thickness/corneal volume1, 7 days and 1 , 3 and 6 months postoperatively
Secondary Outcome Measures
NameTimeMethod
Changes in BCVA1, 7 days and 1, 3 and 6 months postoperatively

Trial Locations

Locations (1)

University Hospital Maastricht

🇳🇱

Maastricht, Netherlands

© Copyright 2025. All Rights Reserved by MedPath